Statement: IV is used as route of administration by the interventions in the primary trial and the secondary trial.
Primary_evidence: INTERVENTION 1:    Treatment (Neoadjuvant Therapy, Adjuvant Therapy)   See Detailed Description.   doxorubicin hydrochloride: Given IV   cyclophosphamide: Given PO   paclitaxel: Given IV   filgrastim: Given SC   capecitabine: Given PO   methotrexate: Given IV   vinorelbine tartrate: Given IV   needle biopsy: Correlative studies   therapeutic conventional surgery: Undergo definitive breast surgery   immunohistochemistry staining method: Correlative studies   trastuzumab: Given IV   tamoxifen citrate: Given PO   letrozole: Given PO   laboratory biomarker analysis: Correlative studies
Secondary_evidence: INTERVENTION 1:    100 mg Q-122   Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days. INTERVENTION 2:    200 mg Q-122   Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.